Item 2.01.
Completion of Acquisition or Disposition of Assets.
On August 1, 2018, pursuant to the terms and conditions of an Agreement and plan of Merger (the Agreement), Enzo Merger Sub was merged with and into Exosome Diagnostics, Inc. (ExosomeDx) with ExosomeDx continuing as the surviving corporation and a wholly-owned subsidiary of the Company (the "Merger"). As part of the Merger, each outstanding share of ExosomeDx common stock was converted into the right to receive the consideration provided in the Agreement.
The Company paid an aggregate of approximately $255 million at the closing of the Merger, which amount included the base merger consideration of $250 million plus adjustments for cash held by ExosomeDx and transaction-related expenses. As described above, the merger consideration was drawn from the Credit Agreement.
A copy of the press release announcing the completion of the Merger is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
